TearLab Announces Fourth Quarter 2015 Preliminary Financial Estimates and Provides Corporate Update
Feb 01, 2016 12:00 pm UTC| Business
SAN DIEGO, Feb. 01, 2016 -- TearLab Corporation (NASDAQ:TEAR) (TSX:TLB) (“TearLab” or “the Company”) announced today certain preliminarily unaudited financial estimates for the fourth quarter of 2015 and provided an...
TearLab Announces Proposed Public Offering of Common Stock
Feb 01, 2016 12:00 pm UTC| Business
SAN DIEGO, Feb. 01, 2016 -- TearLab Corporation (NASDAQ:TEAR) (TSX:TLB) (“TearLab” or “the Company”) announced today its intention to offer, subject to market and other conditions, shares of its common stock in an...
Feb 01, 2016 12:00 pm UTC| Business
LATHAM, N.Y., Feb. 01, 2016 -- Plug Power Inc. (NASDAQ:PLUG), a leader in providing clean, reliable energy solutions, is pleased to announce that New York Senator Charles E. Schumer will visit the Plug Power...
Axsome Therapeutics to Present at the 2016 BIO CEO & Investor Conference
Feb 01, 2016 12:00 pm UTC| Business
NEW YORK, Feb. 01, 2016 -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced...
KVH Industries’ CEO & CFO to Speak at the Cowen and Company 37th Annual Aerospace/Defense Conference
Feb 01, 2016 12:00 pm UTC| Business
MIDDLETOWN, R.I., Feb. 01, 2016 -- KVH Industries, Inc., (Nasdaq:KVHI) chief executive officer, Martin Kits van Heyningen, and chief financial officer, Peter Rendall, will be speaking at the Cowen and Company 37th...
SEC Compliance to Sponsor the 2016 Disruptive Growth & Healthcare Conference
Feb 01, 2016 12:00 pm UTC| Business
LOS ANGELES, Feb. 01, 2016 -- SEC Compliance (www.compliance-sec.com), the fastest growing SEC registered filing agent and financial printer in the United States and a leading provider of regulatory compliance and...
Feb 01, 2016 11:55 am UTC| Business
SOUTH SAN FRANCISCO, Calif., Feb. 01, 2016 -- Portola Pharmaceuticals (NASDAQ:PTLA), announced today that it has licensed lead development and commercial rights to its investigational agent andexanet alfa in Japan to...